Maximilian F Konig, MD
Disclosures: Consulting Fee-argenx (Relationship has ended)|Advisor-ManaT Bio|Consulting Fee-GLG (Relationship has ended)|Consulting Fee-Cello Health BioConsulting (Relationship has ended)|Consulting Fee-Atheneum (Relationship has ended)|Consulting Fee-Third Bridge (Relationship has ended)|Royalties or Patent Beneficiary-ManaT Bio (Methods and Materials for Treating T Cell Cancers)|Stocks or stock options, excluding diversified mutual funds-Doximity - 04/08/2022
No Bio Available.